Companies › ImmunoVaccine Technologies, Inc. (IMV Inc.)
1 active drug program in 4 registered trials: 3 Phase 2, 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DPX-Survivac Survivin-targeted immunogenic peptide vaccine | BIRC5 | Phase 2 | Ovarian Cancer; Relapsed Diffuse Large B-cell Lymphoma; Advanced Cancer; Breast Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04895761 | DPX-Survivac | Phase 1 | Breast Cancer | Oncology | Jun 2023 |
| NCT03836352 | DPX-Survivac | Phase 2 | Ovarian Cancer | Oncology | Dec 2023 |
| NCT04920617 | DPX-Survivac | Phase 2 | Relapsed Diffuse Large B-cell Lymphoma | Oncology | Oct 2024 |
| NCT03029403 | DPX-Survivac | Phase 2 | Advanced Cancer | Oncology | Dec 2025 |
–
Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.